Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of “Buy” from Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $11.6667.

Several brokerages recently weighed in on EPRX. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Quadrature Capital Ltd purchased a new stake in Eupraxia Pharmaceuticals during the 2nd quarter valued at $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals in the third quarter worth $65,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the third quarter valued at $71,000. Bank of America Corp DE lifted its holdings in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after acquiring an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares during the last quarter.

Eupraxia Pharmaceuticals Price Performance

EPRX opened at $7.34 on Friday. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $7.37. The stock has a 50-day moving average price of $6.11 and a 200-day moving average price of $5.60. The firm has a market cap of $263.95 million, a PE ratio of -8.44 and a beta of 1.38.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.04. As a group, sell-side analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.